Marfan syndrome. Part 2: treatment and management of patients
- PMID: 20351702
- DOI: 10.1038/nrcardio.2010.31
Marfan syndrome. Part 2: treatment and management of patients
Abstract
Aortic disease is the main cause of death among patients with Marfan syndrome. Before the development of open surgery, most patients died in the fourth decade of life. Improvements in surgical techniques have facilitated prophylactic surgery and have dramatically changed the life expectancy of patients with Marfan syndrome. Valve-sparing techniques are becoming the standard surgical treatment for these patients, since the operative and long-term results are comparable with those obtained with the Bentall and De Bono procedure and their theoretical advantages over the Bentall and De Bono procedure are attractive for young patients. Distal aortic complications still cause substantial morbidity in patients who have undergone surgery. On the other hand, several medical approaches have appeared as alternatives or adjuncts to the standard treatment with beta-blockers. Mouse models of the disease have shown that the angiotensin II receptor blocker losartan can rescue the phenotype. Among female patients, pregnancy deserves special consideration. Aortic dissection occurs mainly in the third trimester of gestation and in patients with dilated aortas. As aortic dissection carries a high risk of maternal mortality and fetal demise, prophylactic aortic surgery is recommended before attempting pregnancy for those women with an aortic diameter exceeding 40 mm.
Similar articles
-
Repair of left coronary artery aneurysm, recurrent ascending aortic aneurysm, and mitral valve prolapse 19 years after Bentall's procedure in a patient with Marfan syndrome.J Card Surg. 2004 Jan-Feb;19(1):59-61. doi: 10.1111/j.0886-0440.2004.02052.x. J Card Surg. 2004. PMID: 15108794
-
Aortic valve-sparing reimplantation and mitral repair in a pregnant, second trimester Marfan patient: surgical decision.Ann Thorac Surg. 2013 Feb;95(2):701-3. doi: 10.1016/j.athoracsur.2012.06.049. Ann Thorac Surg. 2013. PMID: 23336884
-
Thoracoabdominal aortic aneurysm repair in patients with marfan syndrome.Eur J Vasc Endovasc Surg. 2008 Feb;35(2):181-6. doi: 10.1016/j.ejvs.2007.10.013. Eur J Vasc Endovasc Surg. 2008. PMID: 18069021
-
Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.JAMA Cardiol. 2019 Jul 1;4(7):702-707. doi: 10.1001/jamacardio.2019.1176. JAMA Cardiol. 2019. PMID: 31066871 Review.
-
Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan?J Thorac Cardiovasc Surg. 2008 Feb;135(2):389-94. doi: 10.1016/j.jtcvs.2007.08.047. J Thorac Cardiovasc Surg. 2008. PMID: 18242274 Review.
Cited by
-
The Role of Transforming Growth Factor-β Signaling in Myxomatous Mitral Valve Degeneration.Front Cardiovasc Med. 2022 May 17;9:872288. doi: 10.3389/fcvm.2022.872288. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35656405 Free PMC article.
-
Cardiovascular Management of Adults with Marfan Syndrome.Eur Cardiol. 2016 Dec;11(2):102-110. doi: 10.15420/ecr/2016:19:2. Eur Cardiol. 2016. PMID: 30310455 Free PMC article. Review.
-
Long-term outcomes after aortic root replacement for patients with Marfan syndrome.J Thorac Dis. 2021 Dec;13(12):6779-6789. doi: 10.21037/jtd-21-577. J Thorac Dis. 2021. PMID: 35070362 Free PMC article.
-
TGF-β Signaling-Related Genes and Thoracic Aortic Aneurysms and Dissections.Int J Mol Sci. 2018 Jul 21;19(7):2125. doi: 10.3390/ijms19072125. Int J Mol Sci. 2018. PMID: 30037098 Free PMC article. Review.
-
In vivo phenotypic vascular dysfunction extends beyond the aorta in a mouse model for fibrillin-1 (Fbn1) mutation.Sci Rep. 2024 Mar 9;14(1):5779. doi: 10.1038/s41598-024-56438-y. Sci Rep. 2024. PMID: 38461168 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials